$PFE Company News Stocking stuffers 12:27 p.m. Dec. 17,

New Post Public Reply Private Reply Replies (0) Message Board

Dec 21, 2014 at 12:57 PM

$PFE Company News

Stocking stuffers 12:27 p.m. Dec. 17, 2014 - Mark Hulbert
Boeing’s shares get lift from dividend hike, buyback 7:23 p.m. Dec. 15, 2014 - MarketWatch
U.S. stocks end choppy session lower 4:44 p.m. Dec. 15, 2014 - Barbara Kollmeyer
Pfizer, OPKO Health partner on growth-hormone treatment 1:50 p.m. Dec. 15, 2014 - Angela Chen
Opko Health's stock soars after Pfizer development agreement 8:15 a.m. Dec. 15, 2014 - Tomi Kilgore
Opko's stock jumps 8.8% premarket after Pfizer development agreement 8:07 a.m. Dec. 15, 2014 - Tomi Kilgore
Opko Health, Pfizer team up to develop Opko's GHD treatment 8:06 a.m. Dec. 15, 2014 - Tomi Kilgore
Drug makers face another $65 billion patent cliff 12:41 p.m. Dec. 10, 2014 - Russ Britt
Biogen's Alzheimer's surprise 11:24 a.m. Dec. 9, 2014 - The Trading Deck
Visa, Goldman Sachs powering Dow to 18,000 4:29 p.m. Dec. 5, 2014 - Tomi Kilgore
Will Santa come to Broad and Wall? 1:54 p.m. Dec. 1, 2014 - The Trading Deck
Dow buy signals push index higher 11:39 a.m. Nov. 24, 2014 - The Trading Deck
Are consumers getting gouged on health care? 9:35 a.m. Nov. 22, 2014 - Russ Britt
AstraZeneca advances in London; pound rises as inflation ticks up 11:59 a.m. Nov. 18, 2014 - Carla Mozee
Zoetis unveils $500 million buyback plan 7:52 a.m. Nov. 18, 2014 - Michael Calia
AstraZeneca forecasts revenue of $45 bln by 2023 2:42 a.m. Nov. 18, 2014 - MarketWatch.com
Updates, advisories and surprises 6:01 p.m. Nov. 17, 2014 - MarketWatch
Urban Outfitters slides after earnings miss expectations 4:43 p.m. Nov. 17, 2014 - Sue Chang
U.K. stocks rise on Draghi stimulus talk; AstraZeneca drops 12:04 p.m. Nov. 17, 2014 - Carla Mozee
Pfizer, Germany’s Merck strike deal to develop cancer tumor treatment 11:05 a.m. Nov. 17, 2014 - Natalia Drozdiak

Update: Ligand Wins EU Approval For Duavive 10:02 a.m. Today - Seeking Alpha
New Pfizer bid unlikely says AstraZeneca CEO 7:09 a.m. Today - Seeking Alpha
Holiday Hikes 10:33 p.m. Dec. 19, 2014 - Barrons.com
7 Stocks Providing Their Shareholders A Growing Income With Higher Cash Dividends 10:11 p.m. Dec. 19, 2014 - Seeking Alpha
FDA Approves AstraZeneca Ovarian Cancer Drug 5:12 p.m. Dec. 19, 2014 - The Wall Street Journal Interactive Edition
United Therapeutics Lung Drug Keeps Going And Going 4:20 p.m. Dec. 19, 2014 - Investors Business Daily
Seeking Alpha's Biotech Weekly: A Merck Purchase, Spectacular Auspex, And More 4:00 p.m. Dec. 19, 2014 - Seeking Alpha
Pharma Favorites to Stand the Trials of 2015 2:29 p.m. Dec. 19, 2014 - Barrons.com
Ligand earns milestone payment on EU approval of Duavive 12:48 p.m. Dec. 19, 2014 - Seeking Alpha
Update: AstraZeneca Wins EU Approval For Lynparza 1:13 a.m. Dec. 19, 2014 - Seeking Alpha
Pfizer's Duchenne Muscular Dystrophy Drug in Phase II - Analyst Blog 7:07 p.m. Dec. 18, 2014 - Zacks.com
Halozyme Up on Collaboration and Licensing Deal with J&J - Analyst Blog 6:48 p.m. Dec. 18, 2014 - Zacks.com
Tax Inversions Wrap Up 3:01 p.m. Dec. 18, 2014 - Seeking Alpha
Pfizer Reports Statistically Significant Results for Nerve-Pain Treatment 9:13 a.m. Dec. 18, 2014 - The Wall Street Journal Interactive Edition
Positive Phase 3 results for new formulation of Pfizer pain med 8:52 a.m. Dec. 18, 2014 - Seeking Alpha
Pfizer Is A Great Income Stock On A Pullback 2:29 a.m. Dec. 18, 2014 - Seeking Alpha
Is A Dividend Cut The End Of The World? Analysis Of Dividend-Cutting Companies, Part I 6:04 p.m. Dec. 17, 2014 - Seeking Alpha
Jacobs Drives Organic Growth on Award-Winning Contract - Analyst Blog 5:50 p.m. Dec. 17, 2014 - Zacks.com
Playing the Tax ‘Audit Lottery’ 4:02 p.m. Dec. 17, 2014 - The Wall Street Journal Interactive Edition
OncoGenex's Pancreatic Cancer Study Fully Enrolled - Analyst Blog 3:10 p.m. Dec. 17, 2014 - Zacks.com

Factors Moving Markets: Complementary Research on GlaxoSmithKline, Cintas, Deere, Thermo Fisher and Pfizer 9:10 a.m. Dec. 19, 2014 - PR Newswire - PRF
Pan American Fertilizer (TSX.V: PFE, Frankfurt: 6GF) Provides an Update on its Operations and Audit Filings and Announces Transfer to NEX 12:48 p.m. Dec. 18, 2014 - ACCESSWIRE
Pfizer Reports Top-Line Results From a Phase 3 Study Evaluating Pregabalin Controlled-Release Formulation as a Treatment for Patients With Postherpetic Neuralgia 8:00 a.m. Dec. 18, 2014 - BusinessWire - BZX
Pfizer Initiates Phase 2 Study of PF-06252616 in Duchenne Muscular Dystrophy 8:01 a.m. Dec. 17, 2014 - BusinessWire - BZX
Pfizer Invites Public to View and Listen to Webcast of January 27 Conference Call with Analysts 10:00 a.m. Dec. 16, 2014 - BusinessWire - BZX
Meningococcal Meningitis Survivor and TV Personality Amy Purdy and Pfizer Launch Take Action Against Meningitis 8:02 a.m. Dec. 16, 2014 - BusinessWire - BZX
Pfizer Announces Palbociclib PALOMA-1 Data Published in The Lancet Oncology 6:30 p.m. Dec. 15, 2014 - BusinessWire - BZX
Pfizer Declares First-Quarter 2015 Dividend 12:06 p.m. Dec. 15, 2014 - BusinessWire - BZX
InvestorsObserver releases comments on Pfizer, FedEx, Nike, General Mills, and DR Horton 9:31 a.m. Dec. 15, 2014 - PR Newswire - PRF
Technical Data on Pharma Stocks - Pfizer, Merck, AbbVie, Akorn, and The Medicines 9:10 a.m. Dec. 12, 2014 - PR Newswire - PRF
Actavis Launches Generic Version of Celebrex® 9:28 a.m. Dec. 10, 2014 - PR Newswire - PRF
Pfizer and Brenda Strong Encourage Women to Change the Conversation on Sexual Health Post-Menopause 9:02 a.m. Dec. 10, 2014 - BusinessWire - BZX
Robbins Geller Rudman & Dowd LLP Announces Pendency of Pfizer Inc. Securities Class Action 11:00 a.m. Dec. 9, 2014 - BusinessWire - BZX
New Data at ASH 2014 Highlight Progress of Pfizer’s Growing Portfolio in Blood Cancers 10:30 a.m. Dec. 9, 2014 - BusinessWire - BZX
Spark Therapeutics Announces Gene Therapy Collaboration in Hemophilia B with Pfizer Inc. 8:06 a.m. Dec. 8, 2014 - PR Newswire - PRF
Pfizer Expands Rare Disease Research with Establishment of Gene Therapy Platform 8:02 a.m. Dec. 8, 2014 - BusinessWire - BZX
iTeos Therapeutics Announces License and Collaboration with Pfizer Inc. for Discovery and Development of Cancer Immunosuppression Targets 2:30 a.m. Dec. 8, 2014 - PR Newswire - PRF
Tenet Healthcare Names Dr. Freda C. Lewis-Hall to Board of Directors 4:00 p.m. Dec. 4, 2014 - BusinessWire - BZX
Mylan receives tentative FDA approval for paediatric formulations of abacavir/lamivudine through innovative collaboration with ViiV Healthcare and Clinton Health Access Initiative 11:29 a.m. Dec. 4, 2014 - PR Newswire - PRF
Mylan receives tentative FDA approval for pediatric formulations of abacavir/lamivudine through innovative collaboration with ViiV Healthcare and Clinton Health Access Initiative 10:00 a.m. Dec. 4, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Piramal Pharma FY27 Q2 Results: Robust Growth & Optimism

A Solid Performance from Piramal Pharma The numbers are in, and it's looking pretty good for Piramal Pharma Limited this time around. Their second quarter of fiscal year 2027 has seen some fireworks, and I'm not talking about some half-baked confetti deal. We're talking genuine growth and solid metrics here. Revenue and Profit Surge The headline? Revenue jumped a whopping...

CORE Embraces Tech to Boost Organ Donation Efforts

Innovation Meets Organ Donation Out of all the business moves you hear about, this one rings loud because it doesn’t just move the needle on a spreadsheet—it moves the needle on life or death. The Center for Organ Recovery & Education (CORE) is stepping into the future with a high-tech touch to enhance their lifesaving mission. Partnering with InVita Healthcare...

Anti-Corruption Titans Gather for Key 20-Year IAACA Event

Strength in Unity: A Global Anti-Corruption Gathering Here's a scene you don't stumble upon every day: corruption busters from all corners of the globe converging on Marrakech. The International Association of Anti-Corruption Authorities (IAACA) is rolling out the red carpet for its 20th-anniversary conference, a get-together poised to serve up not just pastries and...

Chemours Faces Class Action over Misleading Guidance

Legal Storm Brewing for Chemours Investors Seems like The Chemours Company, trading under NYSE:CC, is in some legal hot water right now. With the calendar quickly flipping towards December 7, investors are fronted with a crucial choice: step up to stake their claim as lead plaintiff in a securities fraud class action lawsuit, or watch from the sidelines. The Allegations...

Investors Shaken by Better Home’s 28.5% Plunge

Pull up a chair, because Better Home & Finance Holding Company (NASDAQ: BETR) just threw its investors into a frenzy. Mayhem hit when their stock nosedived 28.5% on a single day—May 7, 2026. Let’s untangle what happened and why every shareholder should circle November 20 on their calendar. Unpacking the Fall: A Dive Into Hard Truths So, between mid-March and early May...

CTCA Tackles Trust Issues in $B-illion Card Market

Gaps in a Booming Industry Trading cards might sound like kid stuff, but don’t be fooled—there's billions riding on paper and ink these days. Yet, a dark cloud hovers over the trading card scene, where questions of transparency and accountability loom large. Digital repacks and those dicey randomized packs have folks questioning what’s in the mix: Is it a safe bet...

Beer B Que Music Festival: Hip-Hop, Dancehall & Brews

A Melody and Brew-Infused South Florida Celebration Boy, if festivals were stocks, I'd have bought into the Beer B Que Music Festival years ago. This event, rolling into its seventh year, isn't just another line-up of artists—it feels like a genuine cultural reunion for folks in South Florida. You throw in some heavyweight names like Rick Ross and Kodak Black, plus the...

Infosys Transforms Syngenta's Tech Core to Boost Agility

Unpacking the Syngenta-Infosys Transformation Forget your run-of-the-mill tech upgrade; Infosys has just spearheaded a massive transformation for Syngenta, delivering a new global SAP S/4HANA setup that’s set to turbocharge their Crop Protection business. We’re talking about more than just another software upgrade here—this is a sweeping overhaul affecting 10,000...

Billd's Flex Line: Game-Changer for Subcontractor Credit

Billd's Bold Move Across America Forget piecemeal rollouts; Billd's taking their latest brainchild, Flex Line, right into the heart of America's subcontractor landscape. This isn't some flash-in-the-pan financial offering, either—it's a heavy-hitter poised to shake up the way subcontractors wrangle their working capital. We're talking about a line of credit that's as...

Americans' Faith in Democracy Hits New Lows

Polarization Beyond Politics: A National Reckoning When you catch wind of a report like this one, it's enough to make you feel like the fabric of democracy is unraveling right before our eyes. We're staring at a national identity crisis, folks, and it's got nothing to do with whether you're waving a red or blue flag. This ain't about party lines; it's about a bigger,...